1. Introduction {#sec1}
===============

The vast majority of the proteins require further assistance for acquiring proper maturation and stability; this process described in the late 80s is facilitated through the activity of a family of proteins called "molecular chaperones" or cell stress proteins (CSPs) \[[@B1]\]. This large and diverse group of proteins composed by more than 20 families of proteins and more than 100 proteins includes the heat shock proteins (HSPs) and the thioredoxin (TRX) system. The role of HSPs in cardiovascular diseases (CVDs) has been thoroughly reviewed \[[@B2]\]. In the present paper, we will focus on the role of the TRX system, specifically TRX and peroxiredoxins (PRDXs), in atherothrombosis. For this purpose, we have followed the PRISMA chart displayed in Supplementary Figure  1 (see Suppplementary Figure  1 in supplementary material available online at doi:10.1155/2012/232464).

2. The Thioredoxin  System {#sec2}
==========================

The TRX system mainly comprises TRX, TRX reductase, TRX interacting protein ((TXNIP), vitamin D3-upregulated protein-1 ((VDUP)-1) or TRX-binding protein (TRXBP)), and the PRDXs \[[@B3]\]. The TRX system is involved in protein assembly and plays a key role in cellular redox maintenance.

Under physiological conditions, intra- and extracellular reactive oxygen species (ROS) modulate metabolic, signaling, and transcriptional processes within the cell. However, pathological dysregulation of the redox balance could contribute to CVDs \[[@B4], [@B5]\]. Cellular redox homeostasis is tightly regulated by the coordinated action of NADPH oxidases, the TRX system and glutathione (GSH) \[[@B6]\], among others. The TRX system and GSH are thiol reduction systems with a key role in the defense against excessive ROS production, as well as in the modulation of signaling processes such as inflammation, cellular proliferation, and apoptosis \[[@B7]--[@B9]\]. These molecules maintain the intracellular milieu in a reduced state. GSH is used by the GSH peroxidase to reduce peroxides, producing oxidized GSH (GSSG) while GSH reductase reduces this oxidized form to GSH. The antioxidant properties of TRX result from PRDX action, which recycle H~2~O~2~ through reduction of several hydroperoxides into water and alcohol ([Figure 1](#fig1){ref-type="fig"}).

Depending on their cellular location, TRX/PRDX may exert different functions than their known chaperone and antioxidant activities. This process can be described with the so-called "Moonlighting proteins" theory \[[@B10]\]. This idea supports the notion that one gene = one protein = one function is simple and old-fashioned because large number of proteins have two or more functions. This theory might not apply to every protein but it seems to be right for TRX/PRDX. Under certain circumstances, mainly pro-oxidative conditions, TRX and PRDX could be released to the extracellular milieu \[[@B11], [@B12]\] although their trafficking mechanisms are not yet fully described.

2.1. Intracellular TRX {#sec2.1}
----------------------

TRXs are a class of small redox molecules (\~12 kDa) present in prokaryotes and eukaryotes and are essential for cellular viability \[[@B13]\]. So far, 3 human TRX variants have been characterized codified by different genes. TRX1 is localized under resting conditions in the cytosol but can be translocated upon stress conditions \[[@B14]\] (e.g., it can be found in an oxidized form in the nucleus of exponential growing cells \[[@B15]\] ([Figure 2](#fig2){ref-type="fig"})), TRX2 is mitochondrial \[[@B16], [@B17]\], and SpTRX \[[@B18]\] is abundantly expressed in spermatozoa. TRX has a redox active disulfide/dithiol site within 2 conserved Cys residues \[[@B19]\], and it functions as an antioxidant molecule by protecting cells against H~2~O~2~ \[[@B20]\], regulating heme-oxygenase 1 (HO-1) expression \[[@B21]\], or inducing manganese superoxide dismutase (MnSOD) in the mitochondria \[[@B22]\]. Moreover, it has a protective role against nitric-oxide- (NO-) induced stress, regulating NO synthases activity \[[@B23]\] and through other NO regulating processes \[[@B24]\]. In addition to its role as antioxidant protein, TRX interacts with numerous signaling molecules (including apoptosis signal-regulating kinase 1 (ASK1) and TXNIP) and transcription factors such as nuclear factor-kappa B (NF-*κ*B) and activating protein 1 (AP-1). TRX function can be regulated by redox modification (e.g., NO increases S-nitrosylation of TRX stimulating TRX activity \[[@B25]\]) or by TXNIP binding \[[@B26]\] (reducing TRX activity), among other mechanisms.

Regarding intracellular TRX *in vivo* functions, as TRX-1 KO mice are lethal, some information has been obtained from studies performed in TRX transgenic (Tg) mice \[[@B27]\]. TRX overexpression in mice protects placenta from oxidative stress and fetal growth by augmenting glucose availability \[[@B28]\], and it also functions as a shelter against apoptosis induced by extensive oxidation in diabetic embryopathy \[[@B29]\] or streptozotocin-induced diabetic osteopenia \[[@B30]\]. Furthermore, TRX is able to protect the lung injury provoked by diesel exhaust particles (DEPs) derived from diesel engine-powered automobiles and industrial machines. This protective role, played through AKT modulation, is reflected in the augmented TRX levels in control cells induced by DEP \[[@B31]\]. Also, mediated by AKT signaling, TRX protects neurons against apoptosis during brain focal ischemia \[[@B32]\].

Thus, the major role of TRX in the redox balance is supported by the numerous data regarding the protection exerted by TRX against excessive oxidative damage in different diseases and the embryonic lethality of KO mice for TRX.

2.2. Intracellular PRDX {#sec2.2}
-----------------------

PRDXs are a recent discovery among the peroxidases lacking the hemo group. PRDX protein levels are very abundant, around 0.1--1% of total soluble protein in mammals, and they are ubiquitously distributed in all organisms \[[@B12], [@B33]\]. PRDXs are thiol-specific enzymes lacking selenium, and they use their active sites to reduce peroxides and scavenge ROS \[[@B12]\]. Mammal cells express 6 PRDX isoforms (PRDX 1--6): 1, 2, and 6 are cytosolic, and 3 and 5 are mitochondrial, while 4 is described as a secretory protein in most tissues \[[@B34]\]. Every isoform contains a conserved Cys residue, which is the primary site for H~2~O~2~ oxidation, and they can be further classified according to their Cys residues (PRDX1-4 belongs to the 2-Cys subfamily, PRDX5 or atypical 2-Cys and PRDX6 or 1-Cys PRDX) \[[@B35]\].

PRDXs scavenge H~2~O~2~ more efficiently than other systems such as catalase due to its higher affinity for H~2~O~2~ \[[@B36]\]. PRDX can modulate NADPH oxidase activity through H~2~O~2~ inactivation \[[@B37]\]. In addition, PRDX can also reduce peroxynitrites levels through peroxynitrites reductases \[[@B38]\]. Among the mechanisms modifying PRDX functions, several posttranslational modifications have been described, such as nitrosylation \[[@B39]\], glutathionylation \[[@B40]\], phosphorylation, and the hyperoxidation of its active site \[[@B41]\], which stimulates its chaperone activity \[[@B42]\]. For example, under low H~2~O~2~ concentrations produced in conditions of cellular homeostasis PRDX forms low-molecular-weight oligomers, exerting peroxidase activity. However, under significant changes in H~2~O~2~ concentration, PRDX experiences structural changes and forms high-molecular-weight oligomers and acquires chaperone activity \[[@B43], [@B44]\]. Similarly to TRX, PRDX interacts with several proteins (e.g., cyclophilin A, macrophage inhibitory factor, etc.) and can modulate the function of these binding proteins, in a dependent or independent manner of the PRX redox status \[[@B35]\].

Mice lacking PRDX1 are viable with a phenotype characterized by hemolytic anemia caused by an increased ROS production by red blood cells (RBCs). Furthermore, PRDX1 has tumor suppressor properties as PRDX1 KO mice show an increased rate in malignant tumors as they age, which can be explained by the excessive accumulation of damaged tissue due to extreme ROS production \[[@B45]\]. Similarly to PRDX1 KO mice, targeted disruption of PRDX2 causes cysteine oxidation of several proteins on RBCs membranes, which finally results in augmented levels of denatured protein, cell toxification, and hemolysis \[[@B46]\]. PRDX2 also has been identified as a tumor suppressor gene \[[@B47]\]. Accordingly, PRDX3 (also known as MER5) KO mice are characterized by increased ROS production in macrophages and develop more severe lung injury upon Lipopolisaccharide (LPS) induction, possibly due to an excessive DNA and protein oxidative damage and inflammatory cell infiltration \[[@B48]\]. In fact, it has been calculated that almost 90% of H~2~O~2~ targets PRDX3 within the mitochondrial matrix, playing a major role in redox signaling in the mitochondria \[[@B49]\], protecting the cells against apoptosis induced by excessive damage to mitochondrial macromolecules \[[@B50]\]. PRDX3 absence is also involved in mitochondrial dysregulation associated with obesity, through increased protein carbonylation and ROS production \[[@B51]\]. It is noteworthy that PRDX3 KO adipocytes accumulate more fat than wild type due to hypertrophy and defects in the levels of enzymes implicated in glucose/lipid metabolism \[[@B51]\]. PRDX4 is mostly a secretory protein, while it is attached to the endoplasmic reticulum (ER) membrane of spermatogenic cells in mature testes. In these cells PRDX4 protects from cell death through its antioxidant properties, nonetheless PRDX4 KO spermatozoa shows normal fertilization \[[@B52]\]. To our knowledge there is no PRDX5 KO strain, although it has been described that PRDX5 overexpression prevents ROS production and p53-dependent apoptosis \[[@B53]\]. Nevertheless, KO mice for PRDX6, the only 1-Cys member of the peroxiredoxin family, were more vulnerable to ischemic reperfusion injury as shown by increased infarct size and higher amount oxidative stress \[[@B54]\]. In agreement, PRDX6 overexpression functions as a shelter in mouse lungs against toxicity of hyperoxia \[[@B55]\].

On the whole, the plethora of data regarding the different isoforms of PRDX demonstrate that every subunit, independently of its location, is a member of one of the major cellular systems in charge of scavenging prooxidant species and thus in the maintenance of cellular redox status.

2.3. Extracellular TRX {#sec2.3}
----------------------

TRX expression can be augmented very fast under stress and is secreted by normal and tumor cells although its secretion does not seem to follow a classical Golgi apparatus pathway \[[@B11]\]. TRX location is regulated by TXNIP binding \[[@B26]\] and facilitates TRX transport from cytoplasm to the membrane under oxidative stress \[[@B14]\]. Another mechanism that can be involved in TRX active secretion is the exosomal pathway. Exosomes are small microparticles released by cells upon activation or apoptosis. These vesicles have been implicated in thrombosis, diabetes, inflammation, atherosclerosis, and vascular cell proliferation \[[@B56]\]. Proteomic studies have described the presence of TRX in exosomes in B cells \[[@B57]\], bladder cancer cells \[[@B58]\], colorectal cancer cells \[[@B59]\], and urine \[[@B60]\] ([Figure 2](#fig2){ref-type="fig"}).

There is also a truncated form of TRX that corresponds to the last 80--84 amino acids from the N-terminal end, named TRX80, and it is present in plasma where it was firstly identified as a stimulating factor of eosinophils cytotoxicity \[[@B61]\]. It is possibly a result of protease activity but this process is still unknown ([Figure 2](#fig2){ref-type="fig"}). Recombinant TRX80 is a potent mitogenic cytokine for peripheral blood mononuclear cells (PBMCs), an effect not shared by TRX \[[@B62]\]. TRX80 differs from TRX because it forms a dimer lacking reductase activity and its activity is independent of the Cys residues from the TRX active site. The main cellular target for TRX80 are PBMCs in which it induces a Th1 response via IL12 production \[[@B63]\].

Extracellular TRX is present in the circulation and its levels are increased under oxidative stress or inflammation \[[@B64]\] ([Figure 2](#fig2){ref-type="fig"}). TRX has been pointed out as a biomarker in numerous oxidative and inflammatory diseases such as rheumatoid arthritis (RA) in which plasmaTRXlevels of normal subjects were significantly lower than those of RA patients and correlated with RA disease activity and C-reactive protein \[[@B65]\]. TRX levels were increased in patients with systemic inflammatory stress syndrome (SIRS)/sepsis compared to control subjects  \[[@B66]\].

2.4. Extracellular PRDX {#sec2.4}
-----------------------

PRDX1 can be found inside the Golgi apparatus on endothelial cells (ECs) \[[@B67]\], and under phorbol 12-myristate 13-acetate (PMA) stimulation PRDX1 is translocated to the cellular membrane \[[@B68]\], as also showed for PRDX6 in polymorphonuclear cells (PMNs) \[[@B69]\] ([Figure 2](#fig2){ref-type="fig"}). PRDX might also be secreted by lung cancer cells through a nonclassical pathway \[[@B70], [@B71]\]. Nonetheless, the extracellular function of PRDX is still unknown. Unlike the well-described function of intracellular PRDX1, membrane PRDX6 helps in the maintenance of an optimal NADPH oxidase activity \[[@B69]\]. A number of chaperones, including TRX and HSPs, are released by stressed or dying cells, acting as an endogenous warning system through binding of these signals to receptors on the outer membrane \[[@B72]--[@B75]\]. Most of these signals are recognized by Toll-like receptor 4 (TLR4) \[[@B74], [@B75]\]. Accordingly, PRDX1 binds TLR4 and stimulates proinflammatory cytokine production in macrophages and dendritic cells, which suggests that PRDX could be acting as damage-associated molecular-pattern molecule (DAMP). Its trafficking seems to be dependent on PRDX binding to *protein kinase C* (PKC) through microvesicles \[[@B76]\]. In fact, exosomes can be participating in active transport of PRDX since proteomic studies have described PRDX in exosomes in B cells \[[@B57]\], bladder cancer cells \[[@B58]\], breast cancer cells \[[@B77]\], breast milk \[[@B78]\], colorectal cancer cells \[[@B59]\], and saliva \[[@B79]\] ([Figure 2](#fig2){ref-type="fig"}).

Thus, it is tempting to speculate that extracellular levels of PRDX/TRX result from a cellular response to high oxidant conditions in the outer milieu.

3. TRX/PRDX in Atherothrombosis {#sec3}
===============================

Atherothrombosis is an immune-inflammatory disease, originated by the subendothelial accumulation of LDLs, that can be oxidized by ROS. Oxidative stress is involved not only in the first stages of atherogenesis by modifying LDLs or NO, but also in later stages of atherothrombosis by modulating the expression of proteases that weakens the fibrous cap \[[@B80], [@B81]\]. ROS overproduction also produces direct damage to macromolecules such as lipids, nucleic acids, and proteins \[[@B82]\]. Furthermore, ROS can act as signaling molecules by inducing the activation of several cells from the vasculature. For example, through LDL oxydation and/or direct cell targeting, ROS can induce endothelial dysfunction and further leucocyte activation, deposition, and extravasation. In addition, ROS are clearly involved in the activation of vascular smooth muscle cells (VSMCs) from the lesion and sustain foam cell formation. Thus, pathological ROS overproduction is a main feature in atherogenesis and plaque rupture, which finally results in almost 70% of the clinical events \[[@B83]\].

Among the different systems involved in the redox maintenance in the vasculature, one of the most active is the TRX system. It is present in ECs \[[@B14], [@B84]\], VSMCs \[[@B85], [@B86]\], monocytes/macrophages \[[@B87], [@B88]\], RBCs \[[@B89], [@B90]\], and PMNs \[[@B90], [@B91]\]. Since TRX and PRDX are present in the atherosclerotic plaque and they can modulate different mechanisms involved in CVDs, several studies have addressed their role as diagnostic, prognostic, and therapeutic biomarkers.

3.1. TRX {#sec3.1}
--------

TRX is abundantly expressed in the vasculature, and its levels are increased under oxidative stress, possibly as a response mechanism to augmented ROS production \[[@B19]\]. Besides, TRX expression in the endothelium and in macrophages is augmented in atherosclerotic patients \[[@B92]\] and in arteries damaged by the balloon model \[[@B93]\]. More recently, TRX has been pointed as a possible marker for unstable atherosclerotic plaques due to its association with oxidative stress and intraplaque hemorrhage in culprit lesions \[[@B94]\]. TRX reductase is as well overexpressed in atherosclerotic plaques, maybe synthesized by macrophages engulfing oxLDLs \[[@B95]\].

The antioxidant effects of TRX are shown when overexpressed in mouse hearts, protecting them from myocardial infarction and displaying significantly improved postischemic ventricular recovery \[[@B96]\]. The positive effects of TRX in myocardial infarction are also due to its neoangiogenic properties as shown in different murine models \[[@B97], [@B98]\].

On the other hand, TRX can function as a signaling molecule by decreasing pressure-overload cardiac hypertrophy \[[@B99]\], maybe through upregulation of miR-98 \[[@B100]\]. However, there is a controversy about this matter because almost at the same time it was published another article in which the authors described that activation of TRX participates in the development of pressure-overload cardiac hypertrophy. In this respect, animals overexpressing TXNIP developed less hypertrophy \[[@B101]\]. Furthermore, transverse aortic constriction increased TRX activity accompanied by a 40% reduction in TXNIP levels \[[@B101]\]. Whether variations in TXNIP and TRX levels/activity reflect an increase in oxidative stress or they act as signaling molecules is still a matter to elucidate \[[@B102]\].

Recent studies have shown that extracellular TRX can inhibit interleukin-1 expression stimulated by LPS in monocyte-derived macrophages \[[@B103]\]. Besides, TRX1 administration has beneficial effects on myosin-induced autoimmune myocarditis through inhibition of inflammatory mediators and macrophage infiltration \[[@B104]\] and TRX1 also protects from reperfusion-induced arrhythmias \[[@B105]\]. Furthermore, TRX administration has been also shown to be beneficial in cerebral ischemia/reperfusion injury reducing the infarcted area through its antioxidant properties \[[@B106]\]. As an additional support for the beneficial effects of TRX in therapeutics, it is to note that TRX-1 gene delivery protects hypertensive rats from myocardial infarction through HO-1/B-cell lymphoma 2 (BCL-2) \[[@B107]\].

Regarding cardiovascular diseases, TRX levels are elevated in plasma from atherothrombotic patients \[[@B108], [@B109]\], andhigh homocysteine plus low TRX is related to CAD severity \[[@B110]\]. Furthermore, TRX was elevated in patients following angioplasty, and there was an association with increased TRX levels and decreased rate of restenosis at follow-up angiography (6 months) \[[@B111]\]. We have recently reported an increase in serum TRX from abdominal aortic aneurysm (AAA) patients compared with control subjects. Besides, TRX correlates with AAA size and expansion rate which suggests that TRX could be a good biomarker of AAA evolution \[[@B91]\].

3.2. PRDX {#sec3.2}
---------

PRDX expression can be modified by prooxidative stimulus such as LPS or the phorbol ester12-O-tetradecanoylphorbol- 13-acetate (TPA) \[[@B88], [@B112]\]. Attention to PRDX as a major regulator of H~2~O~2~ homeostasis is growing \[[@B34]\]. In cells stimulated withplatelet-derived growth factor (PDGF) or tumor necrosis factor alpha, PRDX overexpression or silencing provoked, respectively, reduction or increase of H~2~O~2~ levels \[[@B113]\]. Moreover, through H~2~O~2~ scavenging, PRDX can inhibit the NF-*κ*B pathway and consequently the inflammatory response \[[@B114]\]. Different PRDX isoforms seem to modulate different cellular responses. For example, transfection of VSMCs from rat pulmonary artery with an expression plasmid for PRDX1 increases proliferation rate significantly \[[@B115]\]. PRDX1 also diminishes leucocytes activation and adhesion to vascular endothelium. Double KO mice for PRDX1 and ApoE chow fed showed larger atherosclerotic lesions and macrophages enriched than ApoE KO mice \[[@B116]\].KO mice for PRDX2/ApoE showed exacerbated atherosclerotic lesion formation dependent both on vascular and hematopoietic cells. Besides, immune cells accumulation in the atherosclerotic lesions is increased due to PRDX2 absence and also redox-dependent signaling PRDX2 \[[@B117]\]. Moreover, PRDX2 modulates PDGF signaling, inhibiting thereby cell proliferation and migration \[[@B113], [@B118]\]. Using different *in vivo* models, it was shown that CD36 KO mice produce lower levels of ROS, along with an increase in heme-oxygenase1 (HO-1) and PRDX2. Furthermore, NF-E2-related factor-2 (Nrf2), a transcription factor in charge of the transcriptional regulation of HO-1 and PRDX2, knockdown led to increased ROS production and a prothrombotic phenotype under FeCl~3~ treatment, a similar phenotype to that of PRDX2 KO mice \[[@B119]\]. Regarding PRDX2 and vascular diseases, it has been recently shown that PRDX2 is overexpressed in ruptured AAA tissue compared with nonruptured \[[@B120]\]. This could be associated with the increased oxidative stress observed in AAA tissue, which produces 2.5 times higher superoxide than adjacent non-AAA tissue and 10 times higher than nonpathological aorta \[[@B121]\].

Besides, PRDX3 overexpression prevents ventricular remodeling and cardiac failure after myocardial infarction in mice \[[@B122]\]. As mentioned above, PRDX6 protects mice against ischemic reperfusion injury \[[@B54]\]. Although, little is known about circulating levels of PRDX, we have recently described high PRDX1 levels in serum from AAA patients \[[@B90]\]. Besides, PRDX1 levels correlated positively with size and expansion rate of AAA, suggesting its potential role as diagnostic and prognostic biomarker for AAA.

4. Conclusion {#sec4}
=============

On the whole, we have summarized several findings that demonstrate the major role of the TRX system in the maintenance of the redox status in CVDs. Furthermore, the extracellular levels of PRDX/TRX seem to be related with a prooxidative scenario and there is growing data suggesting their potential role as biomarkers for oxidative-stress-related diseases. Finally, their value as useful therapeutic tools is being tested and future studies are necessary to validate thier prospective beneficial effects in CVDs.
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